Zomacton® (somatropin) – New indications
July 19, 2018 - Ferring announced the FDA approval of Zomacton (somatropin), for the treatment of pediatric patients with short stature associated with Turner syndrome; idiopathic short stature, height standard deviation score ≤ -2.25 and associated with growth rates unlikely to permit attainment of adult height in the normal range; short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency; and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age.
Top